Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Genitourinary 1

Conditions

Breast Neoplasms 17Carcinoma, Renal Cell 14Neoplasms 12Neoplasm Metastasis 9Neuroendocrine Tumors 7Head and Neck Neoplasms 7Kidney Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Insulinoma 2Hodgkin Disease 2

Interventions

Everolimus 2spartalizumab 1pazopanib 1guadecitabine 1gallium Ga 68 dotatate 1Nivolumab 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Paraganglioma × Everolimus × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡